ArticlePloS one2025
Development of a new cell isolation device FlowMagicTM.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Betaine supplementation modulates mitochondrial and redox-related adaptations in premenopausal women with overweight: a randomized controlled trial.European journal of nutrition · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolation of human peripheral blood mononuclear cells (PBMCs) from blood typically involves a density gradient medium during density centrifugation. The problem of increasing red blood cell (RBC) and granulocyte (GRA) contamination during PBMC isolation as the elapsed time after blood collection increases remains unresolved. As a countermeasure against RBC contamination, hemolysis treatment is available; however, these extra steps are laborious, time-consuming, and could introduce artifacts. To overcome this challenge, we developed a novel isolation device, FlowMagic™, which features a proprietary two-layer insert structure designed to prevent RBC and GRA contamination during PBMC isolation from blood. The efficacy of this method was evaluated by isolating PBMCs from donors and analyzing immune cell populations by flow cytometry. Compared to SepMate (median (Q50) = 11.0, interquartile ranges (IQR): 8.8-19.5; p < 0.01) and Lymphoprep methods (Q50 = 9.3, IQR: 6.6-13.5; p < 0.01), FlowMagic™ achieved significantly greater reduction in RBC contamination to below detectable limits (Q50 = 0.0, IQR: 0.0-0.0), with sustained efficacy observed up to 72 hours post-collection. Additionally, the FlowMagic™ method (Q50 = 2.5, IQR: 0.5-3.4, at 48 hours, median = 4.5, IQR: 2.1-10.3, at 72 hours, respectively) significantly reduced GRA contamination compared with the SepMate (Q50 = 12.0, IQR: 7.8-25.5, at 48 hours, Q50 = 27.5, IQR: 12.3-29.0, at 72 hours, respectively; p < 0.01) and Lymphoprep methods (Q50 = 10.5, IQR: 6.9-19.8, at 48 hours, Q50 = 17.5, IQR: 13.3-23.5, at 72 hours, respectively; p < 0.01) at 48 and 72 hours after blood collection. Furthermore, the recovery rates of CD3 + , CD4 + , CD8 + , CD19 + , and CD16/56 + cells in the FlowMagic™-isolated PBMCs (Q50 = 8.6, 5.9, 2.5, 1.3, and 1.9, respectively) were significantly improved compared to those in SepMate- (Q50 = 2.2, 1.5, 0.7, 0.4, and 0.5, respectively; p < 0.01) and Lymphoprep-isolated PBMCs (Q50 = 2.4, 1.5, 0.8, 0.6, and 0.8, respectively; p < 0.01), even at 48 hours after blood collection. These findings suggest that the PBMC isolation method using FlowMagic™ is advantageous in preventing RBC and GRA contamination for research, diagnostic, and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.